Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy

The aim of this study was to evaluate the efficacy and safety of intratumoral injection of toluenesulfonamide(PTS) in combination with or without first-line chemoimmunization based on standard treatment for stage IV driver gene-negative non-small cell lung cancer.

Trial Details

NCT ID

NCT06607796

Phase

PHASE3

Sponsor

Zhou Chengzhi

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Toluenesulfonamide (PTS) Intratumoral Injection

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

Fully understand, be informed about the study and sign the Informed Consent Form (ICF); be willing to follow and be capable of completing all trial…
Age ≥18 years and ≤75 years at the time of signing the ICF；
Histologically or cytologically confirmed stage IV (AJCC 8th edition) driver gene negative non-small cell lung cancer；
At least one measurable target lesion assessed by the investigator according to the requirements of RECIST 1.1 within 4 weeks prior to enrollment, …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →